Literature DB >> 7529717

Plasmodium falciparum: a comparison of the activity of Pfs230-specific antibodies in an assay of transmission-blocking immunity and specific competition ELISAs.

W Roeffen1, P J Beckers, K Teelen, T Lensen, R W Sauerwein, J H Meuwissen, W Eling.   

Abstract

The activity of monoclonal antibodies (mAbs) that specifically recognize the Plasmodium falciparum sexual stage-specific protein Pfs230 was analyzed. All mAbs reacted with the surface of extracellular sexual forms of the parasite in a suspension immunofluorescence antibody reaction and precipitated the Pfs230 protein from an NP-40 extract of surface radioiodinated macrogametes/zygotes. Only mAb that bound complement blocked transmission, whereas mAb that did not bind complement but competed with the complement-binding mAb for binding to the same epitope did not block transmission. These mAbs were used to develop Pfs230-specific competition ELISAs to analyze epitope diversity and to analyze the binding characteristics of anti-Pfs230 antibodies in human serum. Transmission-blocking (TB) antibodies in test/field sera competed in the competition ELISA for binding with epitope-specific, labeled mAbs against Pfs230. At least five different epitope regions could be defined with the competition ELISAs. All 46 sera from gametocyte carriers immunoprecipitated the Pfs230 molecule, while 19 of these sera blocked transmission in the bioassay. Five of the transmission-blocking and one of the nonblocking sera competed with monoclonal antibodies. A method comparison analysis was used to determine agreement between reactions in a competitive ELISA and the TB activity examined in the bioassay. The index of agreement kappa between outcomes of the bioassay and ELISA was fair to poor (kappa = 0.25) but since its range includes values below 0 the relation between the data obtained by the bioassay and the competition ELISA can be explained by chance alone. The serological data did not reveal a correlation between immunoprecipitation of Pfs230 and TB activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7529717     DOI: 10.1006/expr.1995.1003

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  12 in total

1.  Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230.

Authors:  Nicholas J MacDonald; Vu Nguyen; Richard Shimp; Karine Reiter; Raul Herrera; Martin Burkhardt; Olga Muratova; Krishan Kumar; Joan Aebig; Kelly Rausch; Lynn Lambert; Nikiah Dawson; Jetsumon Sattabongkot; Xavier Ambroggio; Patrick E Duffy; Yimin Wu; David L Narum
Journal:  J Biol Chem       Date:  2016-07-18       Impact factor: 5.157

Review 2.  Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America.

Authors:  Myriam Arévalo-Herrera; Yezid Solarte; Catherin Marin; Mariana Santos; Jenniffer Castellanos; John C Beier; Sócrates Herrera Valencia
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

Review 3.  Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination.

Authors:  Teun Bousema; Chris Drakeley
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

Review 4.  The s48/45 six-cysteine proteins: mediators of interaction throughout the Plasmodium life cycle.

Authors:  Silvia A Arredondo; Stefan H I Kappe
Journal:  Int J Parasitol       Date:  2016-11-27       Impact factor: 3.981

5.  Complement-mediated lysis of Plasmodium falciparum gametes by malaria-immune human sera is associated with antibodies to the gamete surface antigen Pfs230.

Authors:  J Healer; D McGuinness; P Hopcroft; S Haley; R Carter; E Riley
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

6.  Naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs48/45 and Pfs230 in an area of seasonal transmission.

Authors:  André Lin Ouédraogo; Will Roeffen; Adrian J F Luty; Sake J de Vlas; Issa Nebie; Edith Ilboudo-Sanogo; Nadine Cuzin-Ouattara; Karina Teleen; Alfred B Tiono; Sodiomon Bienvenu Sirima; Jan-Peter Verhave; Teun Bousema; Robert Sauerwein
Journal:  Infect Immun       Date:  2011-10-03       Impact factor: 3.441

7.  A plant-produced Pfs230 vaccine candidate blocks transmission of Plasmodium falciparum.

Authors:  Christine E Farrance; Amy Rhee; R Mark Jones; Konstantin Musiychuk; Moneim Shamloul; Satish Sharma; Vadim Mett; Jessica A Chichester; Stephen J Streatfield; Will Roeffen; Marga van de Vegte-Bolmer; Robert W Sauerwein; Takafumi Tsuboi; Olga V Muratova; Yimin Wu; Vidadi Yusibov
Journal:  Clin Vaccine Immunol       Date:  2011-06-29

8.  Structural basis for recognition of the malaria vaccine candidate Pfs48/45 by a transmission blocking antibody.

Authors:  Frank Lennartz; Florian Brod; Rebecca Dabbs; Kazutoyo Miura; David Mekhaiel; Arianna Marini; Matthijs M Jore; Max M Søgaard; Thomas Jørgensen; Willem A de Jongh; Robert W Sauerwein; Carole A Long; Sumi Biswas; Matthew K Higgins
Journal:  Nat Commun       Date:  2018-09-20       Impact factor: 14.919

9.  Low Levels of Human Antibodies to Gametocyte-Infected Erythrocytes Contrasts the PfEMP1-Dominant Response to Asexual Stages in P. falciparum Malaria.

Authors:  Jo-Anne Chan; Damien R Drew; Linda Reiling; Ashley Lisboa-Pinto; Bismarck Dinko; Colin J Sutherland; Arlene E Dent; Kiprotich Chelimo; James W Kazura; Michelle J Boyle; James G Beeson
Journal:  Front Immunol       Date:  2019-01-14       Impact factor: 7.561

10.  A novel polyclonal antibody-based sandwich ELISA for detection of Plasmodium vivax developed from two lactate dehydrogenase protein segments.

Authors:  Luciana Pereira Sousa; Luis André Morais Mariuba; Rudson Jesus Holanda; João Paulo Pimentel; Maria Edilene Martins Almeida; Yury Oliveira Chaves; Davi Borges; Emerson Lima; James Lee Crainey; Patricia Puccinelli Orlandi; Marcus Vinicius Lacerda; Paulo Afonso Nogueira
Journal:  BMC Infect Dis       Date:  2014-01-30       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.